News Releases

Patent Pending for Novel Antimicrobial-Development Technology Stemming from IBBR Collaboration

CaptCpl-1 is a pneumococcal-specific endolysin composed of a GH25 enzyme active domain (EAD) and a cell wall binding domain (CBD). PlyCA contains two EADs, GyH and CHAP, but has no activity against pneumococcus. ClyX-1 is a chimeric endolysin, made from insertion of the Cpl-1 CBD in between the two PlyCA EADs. ClyX-1 not only has activity against pneumococcus, but its activity is 100-fold higher than Cpl-1, presumably due to synergistic activities of the two PlyCA EADs and specificity provided by the Cpl-1 CBD.

January 22, 2021 - A group of NIST and University of Maryland scientists has... Read More

Consortium Led by IBBR Fellow John Moult Fosters Advances in Protein Structure Prediction

Part of a plant virus glycoprotein. Computed structure blue, experiment magenta

January 19, 2021 -  Reports from the recent 14th Critical Assessment of Structure Prediction (CASP) community experiment show substantial progress in computing the structure of protein molecules. The three-dimensional structure of proteins provides key insights into understanding many aspects of their function, including disease mechanisms, the effect of genetic mutations, and facilitates the development of new therapeutics and vaccines. IBBR Fellow. Dr. John... Read More

IBBR Fellow Contributes to Research Team That Characterizes the Structure of a Respiratory Syncytial Virus Vaccine Candidate

Arrangement of the RSV F fusion protein trimers around the nanoparticle carrier core in the vaccine material, as determined by solution X-ray and neutron scattering.

January 14, 2021 - IBBR Fellow Alexander Grishaev and collaborators at the National Institute of Standards and Technology (NIST) and Novavax characterized the structure of a nanoparticle vaccine candidate for Respiratory Syncytial Virus (RSV), a virus that can cause severe respiratory infections in children. The team applied advanced biophysical measurement... Read More

IBBR Publishes 2020 Issue of BioNEXUS Magazine

January 11, 2021 -- The Institute for Bioscience and Biotechnology Research (IBBR) is pleased to share the second issue of BioNEXUS magazine.   

BioNEXUS highlights IBBR's efforts to advance understanding of the structure and function of biomolecules and biological systems and to apply these discoveries to analytical tool innovation and to disease prevention and treatment.

The current issue of BioNEXUS includes a feature on The Next Vaccine: How Far We Have Come and the Hope for Tomorrow as well as stories about therapeutic discovery,... Read More

IBBR Fellow Zvi Kelman Receives Department of Commerce Gold Medal Award

December 7, 2020 – IBBR Fellow Zvi Kelman has been recognized for scientific achievement with the Department of Commerce Gold Medal Award. Dr. Kelman, Director of the Biomolecular Labeling Laboratory at the National Institute of Standards and Technology (NIST) and Adjunct Professor at the Department of Cell Biology and Molecular Genetics, University of Maryland College Park, received this award as a member of a NIST research team on the project “Developing a suite of standards including the first NIST living reference material to strengthen the nation's response to potential biothreats”.... Read More

Protein Structures Identified by IBBR Team Provide Insights into T Cell Recognition of Targets for Cancer Therapies

August 4, 2020 – Adoptive T cell therapy (ACT) is a treatment for patients with several forms of cancer. This therapeutic effect is mediated by T cells through recognition of tumor neoantigens, which are proteins not previously recognized by the immune system. To better understand interactions between neoantigens and T cell receptors (TCRs) that could impact therapeutic development, a team in the laboratory of IBBR Investigator Dr. Roy Mariuzza, Professor, UMCP Department of Cell Biology and Molecular Genetics, in collaboration with IBBR Fellow Brian Pierce, Assistant Professor, UMCP... Read More

Assuring Quality of Vaccines at the Point-of-Care: IBBR Team Advances Detection Method

June 08, 2020 - Analytical techniques to evaluate the condition of vaccine formulations are critical to quality assurance of these substances. Certain vaccines, including those with aluminum adjuvants, can be sensitive to freezing, which would damage the vaccine, and therefore deviations from temperature ranges prescribed for storage and transport need to be monitored. A method for detecting freezing events of liquid vaccines is described in a recent publication in the journal Vaccine featuring work by the laboratory of Bruce Yu, PhD, a professor of pharmaceutical sciences at the... Read More

IBBR Laboratory Develops a Database of Coronavirus Protein Structures, CoV3D, to Facilitate Advances in COVID-19 Research

June 8, 2020 - In response to the global COVID-19 pandemic, researchers across the world have been working to rapidly develop tests, vaccines, and therapeutics. High resolution structures of coronavirus proteins are critical to understanding the virus and how it causes disease, as well as how the immune system recognizes the virus, which can be used to design effective vaccines and antibody-based therapeutics. To provide a simple and up-to-date reference of coronavirus structural data to the scientific community, a team in the laboratory of IBBR... Read More

IBBR Researchers Awarded $850K from NSF to Study How Plants Defend Against Fungal Invasion

(Rockville, MD, February 25, 2020) Researchers at the Institute for Bioscience and Biotechnology Research (IBBR) recently received $850K from the National Science Foundation (NSF) to advance our understanding of how fungi like powdery mildew infect plants including food source crops, and how plants fight back.  The will support advances in sustainable farming by revealing the mechanisms that fungi use to infect plants.

Kunal Kundu Receives Outstanding Graduate Assistant Award

February 13, 2020 - Please join us in congratulating Kunal Kundu for receiving an Outstanding Graduate Assistant Award from the UMCP Graduate School.